Dissertation Defence: Dani Flinkman
Dani Flinkman defended his PhD entitled “Proteomics analysis of Parkinson’s disease mechanism and biomarkers” on May 17th. The opponent was Daniel Otzen from Aarhus University.
Summary of the dissertation
Parkinson’s disease (PD) is the second most common neurodegenerative disease without a cure and a single known cause. The disease is characterized by the loss of the dopaminergic neurons in the mid brain, and causes progressive motor symptoms as well non motor symptoms such as depression and defects in smelling ability. Although there is no single cause to the disease, up to ~15% of sporadic PD patients have monogenic mutations associated with PD. Roughly 3% of individuals suffering from PD have a mutation in leucine-rich repeat kinase 2, causing increased kinase activity and the most common LRRK2 mutation is glycine 2019 to serine (G2019S). PD patients with LRRK2 have almost indistinguishable symptoms to PD cases and LRRK2 activation is present in sporadic PD. Proteins rarely function alone, and to study complex diseases it becomes important to understand how proteins function together to create a phenotype. Mass-spectrometry based proteomics is the modern field of science suitable for studying protein networks.
The work presented in the thesis presented a novel function for LRRK2 in suppressing protein synthesis, and data analysis tool for studying kinase function from proteomics data. We found that LRRK2 phosphorylates ribosomal sub-fraction of the rodent brain and in rodent model of PD many important protein synthesis arrest checkpoints are turned on. We also found that LRRK2 kinase activity in neurons and PD patient fibroblasts in both sporadic and G2019S form of PD functions to suppress protein synthesis. To gain understanding what are the proteins that are affected by LRRK2 mediated protein synthesis suppression, we performed unbiased newly synthesized proteome screen to identify, and targeted proteomic experiment to validate the changes in sporadic and LRRK2 G2019S patient fibroblasts. We observed that in both sporadic and G2019S PD proteins related to proteostasis regulation are downregulated. The findings shed light on possible key players disturbed in PD and potential novel biomarkers of PD. Finally to understand complex kinase signaling we developed an automated pipeline to study proteomic phosphorylation data: PhosPiR. PhosPiR performs data quality control, statistical analysis, functional enrichment analysis and kinase pathway and activation analysis from the complex phosphorylation data. This simplifies complex data analysis and allows a non-bioinformatician to analyse the phosphorylation data coming from proteomics experiments
Recent Posts
- BioCity Turku asks for proposals for Elias Tillandz publication prize winner during March 2026In the context of the 35th BioCity Symposium “Vision, Expanded” (27-28 August 2026) the twenty-second Read moreMarch 3, 2026
- Rector Widen Visited Our Centre Åbo Akademi University Rector, Gunilla Widén, visited our Centre on Wednesday, February 25th, to learn Read moreFebruary 27, 2026
- Laura Elo is awarded the Leif C. Groop Award for outstanding research on type 1 diabetesLaura Elo a group leader at Turku Bioscience is awarded the Leif C. Groop Award Read moreFebruary 23, 2026
- Finnish Cultural Foundation Awards Funding to Turku Bioscience ResearchersWe are pleased to announce recent funding from The Finnish Cultural Foundation: Congratulations to all Read moreFebruary 16, 2026
- Newly discovered gut microbial molecules in infancy may influence the risk of type 1 diabetesAn international research team has uncovered compelling evidence that gut-microbe-derived molecules may play an important Read moreJanuary 20, 2026
- Turku Bioscience Centre Is Recruiting New Research LeadersTurku Bioscience Centre is currently inviting applications for two key research positions that will strengthen Read moreJanuary 13, 2026